Urogen Pharma (URGN) Live Share Price, Invest From India

Urogen Pharma Stock Performance

as on October 5, 2026 at 2:15 pm IST

Day's Low
Day's High
$40.10
Day's Price Range
$41.82
$41.40
3.14%
Downside
1.01%
Upside
52 Week's Low
52 Week's High
$15.86
52-Week Price Range
$50.81
$41.40
61.69%
Downside
22.73%
Upside

Urogen Pharma share price movements today

Previous Close: $40.55
Open: $40.73
Volume: 723.4K
Market Cap: $2.0B
Day's Low - High: $40.10 - $41.82
52 Week Low - High: $15.86 - $50.81

Urogen Pharma Historical Returns

1 Month Return: -6.1 %
3 Month Return: + 8.89 %
1 Year Return: + 137.93 %
3 Year Return: + 205.54 %
5 Year Return: + 143.96 %

Urogen Pharma Stock Fundamentals & Key Indicators

Check Urogen Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.0B

EPS (TTM)

-1.98

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-20.91

Industry PE ratio

-11.70

PEG Ratio

-0.42

EBITDA

-70.7M

Revenue (TTM)

188.7M

Profit Margin

90.85%

Return On Equity TTM

81.78%

Urogen Pharma vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Urogen Pharma with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Urogen Pharma	StrongBuy	$2.0B	143.96%	-20.91	90.85%	0.00%
Revolution Medicines	StrongBuy	$44.3B	637.21%	-23.32	0.00%	0.00%
Moderna	Neutral	$75.9B	-42.79%	-23.81	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$127.9B	185.14%	29.14	86.04%	0.00%
Regeneron	Buy	$75.7B	33.45%	17.55	84.86%	0.50%

Stock Returns calculator for Urogen Pharma Stock including INR - Dollar returns

The Urogen Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Urogen Pharma investment value today

Current value as on today

₹2,58,256

Returns

₹1,58,256

(+158.26%)

Returns from Urogen Pharma Stock

₹1,37,931 (+137.93%)

Dollar Impact

₹20,325 (+20.33%)

Analyst Recommendation on Urogen Pharma Stock

Based on 5 analysts

BUY

80.00%

Buy

20.00%

Hold

0.00%

Sell

Based on 5 analysts, 80% of analysts recommend a 'BUY' rating for Urogen Pharma. Average target price of $60

Urogen Pharma Share Price Target

Get share price movements and forecasts by analysts on Urogen Pharma.

What analysts predicted

31%UPSIDE

Target Price

$60

Current Price

$41.4

Analyzed by

5 Analysts

High

$75

Target

$60.00

Low

$48

Urogen Pharma target price $60, a slight upside of 31% compared to current price of $41.4. According to 5 analysts rating.

Indian Investors' Interest in Urogen Pharma Stock

Search interest for Urogen Pharma Stock has increased by 30% in the last 30 days, reflecting an upward trend in search activity.

Time period: September 5, 2026 to October 5, 2026

Change:30% versus previous 30 day period

Urogen Pharma Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	18	21	25	24	20	24	27	37	50	72
Gross Profit	17	19	22	22	17	20	24	34	46	65
Operating Income	-25	-25	-17	-27	-36	-41	-27	-19	-20	0
EBITDA	-23	-29	-14	-26	-38	-48	-25	-22	-19	-3
Interest Expense	2	3	2	3	4	8	7	13	8	4
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-32	-33	-23	-34	-43	-48	-34	-26	-28	-8
Income Tax Expense	0	0	0	2	0	1	-1	0	-4	5
Net Income	-32	-33	-23	-37	-43	-49	-33	-26	-23	-14
Net Profit Margin	90.80%	89.80%	90.27%	89.94%	88.50%	85.34%	88.07%	91.31%	91.88%	90.93%

Urogen Pharma Annual Profit & Loss

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	8	1	0	11	48	64	82	90	109
Gross Profit	7	0	0	10	42	56	73	81	97
Operating Income	-19	-77	-109	-126	-92	-79	-65	-96	-124
EBITDA	-19	-77	-108	-122	-108	-76	-60	-95	-135
Interest Expense	-	-	0	0	17	8	14	12	33
Depreciation	0	0	1	2	0	1	1	0	2
Income Before Tax	-19	-75	-105	-125	-109	-108	-98	-124	-153
Income Tax Expense	0	0	-	3	1	1	3	2	0
Net Income	-20	-75	-105	-128	-110	-109	-102	-126	-153
Net Profit Margin	92.65%	-59.84%	100.00%	91.45%	89.27%	88.11%	88.68%	90.18%	88.66%

Urogen Pharma Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-32	-33	-23	-37	-43	-49	-33	-26	-23	-14
Operating Cash Flow	-31	-23	-27	-13	-42	-39	-42	-38	-45	-33
Investing Cash Flow	13	11	-106	60	-25	28	31	27	-20	1
Financing Cash Flow	54	100	39	0	0	0	8	31	65	0
Change in Cash	36	88	-94	47	-67	-11	-2	20	0	-30

Urogen Pharma Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-20	-75	-105	-128	-110	-109	-102	-126	-153
Operating Cash Flow	-9	-37	-71	-105	-84	-87	-76	-96	-162
Investing Cash Flow	-36	35	-145	93	4	1	0	-20	61
Financing Cash Flow	61	66	165	16	72	97	116	194	39
Change in Cash	15	64	-51	3	-8	10	39	77	-60

Global Institutional Holdings in Urogen Pharma

Check out the Institutions with significant holdings in Urogen Pharma.

Funds	Holdings
iShares	4.61%
American Century Mutual Funds, Inc.	1.79%
Michael Rockefeller	1.02%
Vanguard	0.95%
Fidelity Salem Street Trust	0.88%

See all

Insights on Urogen Pharma

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 3 Years
In the last 3 years, URGN has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 5 quarters, -49.94M → -14.35M (in $), with an average increase of 38.1% per quarter
POSITIVE IMPACT
Price Rise
In the last 6 months, URGN stock has moved up by 120.0%
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 6 quarters, 20.25M → 72.45M (in $), with an average increase of 22.2% per quarter
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 429.0%

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Organisation	Urogen Pharma
Headquarters	400 Alexander Park Drive, Princeton, NJ, 08540, US
Industry	Biotechnology
CEO	Elizabeth Barrett

Key Management of Urogen Pharma

Name	Title
Ms. Alison Hardgrove	Senior Vice President of Human Resources
Mr. James Ottinger R.ph.	Executive Vice President of Regulatory Affairs & Quality
Mr. Michael J. Louie M.D., M.P.H., M.Sc.	Chief Development Officer
Mr. Timothy Simon	Senior Vice President of Business Development & Portfolio Strategy
Ms. Elizabeth A. Barrett	President, CEO & Director
Mr. Jason Drew Smith J.D.	General Counsel, Chief Compliance Officer & Corporate Secretary
Dr. Mark P. Schoenberg M.D.	Chief Medical Officer
Mr. Christopher Degnan CPA	Chief Financial Officer
Mr. Vincent I. Perrone	Senior Director of Investor Relations
Dr. Marina Konorty Ph.D.	Executive Vice President of Research & Development and Technical Operations

FAQs

What is Urogen Pharma share price today?

Urogen Pharma share price today is $41.40 as on October 5, 2026 at 8:45 am IST at the close of the market. Urogen Pharma share today touched a day high of $41.82 and a low of $40.10.

What is the 52 week high and 52 week low for Urogen Pharma share?

Urogen Pharma share touched a 52 week high of $50.81 on August 19, 2026 and a 52 week low of $15.86 on October 10, 2025. Urogen Pharma stock price today i.e. October 5, 2026 at 8:45 am IST is closed at $41.40,which is 18.52% down from its 52 week high and 161.03% up from its 52 week low.

What is Urogen Pharma's market capitalisation today?

Urogen Pharma market capitalisation is $0.00T as on October 5, 2026 at 8:45 am IST.

How to invest in Urogen Pharma Stock (URGN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Urogen Pharma on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Urogen Pharma Stock (URGN) from India?

Indian investors can start investing in Urogen Pharma (URGN) shares with as little as ₹96.300003051758 or $1 (as of October 5, 2026 at 11:44 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in Urogen Pharma stock (as per the Rupee-Dollar exchange rate as on October 5, 2026 at 11:44 am IST). Based on Urogen Pharma share’s latest price of $41.40 as on October 5, 2026 at 8:45 am IST, you will get 0.2415 shares of Urogen Pharma. Learn more about fractional shares .

What are the returns that Urogen Pharma has given to Indian investors in the last 5 years?

Urogen Pharma stock has given 143.96% share price returns and 29.14% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?